The $76 Billion CVS Business You've Probably Never Heard Of

CVS Caremark operates a mammoth business that racks up billions, but most people don't even know it exists.

Aug 24, 2014 at 1:06PM

Despite the fact that it brought in almost three times as much revenue as Nike last year, you probably haven't heard of CVS Caremark's (NYSE:CVS) "other" business -- the one that doesn't involve retail pharmacies on street corners, yet brought in the majority ($76 billion of $127 billion) of revenue last year. 

That business, which operates under a handful of names including, most notably, Caremark, helps healthcare payers deliver prescriptions more cheaply to patients. Since CVS' pharmacy services business is relatively unknown among big national companies, let's take a closer look.

G

Source: CVS Caremark

Connecting the dots
CVS' pharmacy services business is a pharmacy benefit manager, or PBM. Its clients include healthcare insurers and companies and organizations that self-insure employee healthcare plans.

The primary goal of PBMs is to save payers money. Much like a national footwear chain negotiates with Nike for the lowest price on its latest running shoe, PBMs leverage the buying power of many different companies to negotiate cut-rate deals with drugmakers.

Those deals allow insurers to deliver patients prescribed medicine for less than it would cost them if they negotiated with drugmakers directly; however, PBMs don't just orchestrate rock-bottom drug prices. They also provide other services including making sure patients use less-costly generics when they're available, mail order pharmacies which can deliver drugs at a lower cost, and management programs like Pharmacy Advisor, which helps ensure that plan members are adhering to their medication regiments, which can help reduce expensive hospitalizations.

Protecting its moat
In 2007, PBMs like Caremark, Express Scripts, and Catamaran were increasingly winning away prescriptions from pharmacies like CVS by delivering convenient, 90-day prescriptions directly to patient doors.

That threat helped prompt CVS to outbid rivals to acquire Caremark, one of the nation's largest PBMs.

The deal catapulted CVS forward; revenue jumped from $43 billion in 2006 to more than $132 billion over the trailing-12 months. CVS' operating profit has similarly climbed following the Caremark acquisition, growing from $2.4 billion in 2006 to $8 billion in 2013.

CVS Revenue (TTM) Chart

CVS Revenue (TTM) data by YCharts

Planning ahead
The cost of medicine is growing rapidly as new personalized drugs make their way through expensive clinical trials to market. This next generation of drugs aims to improve patient outcomes, but does so at a steep price.

Many new expensive drugs are coming to the market (think multiple sclerosis drugs Tecfidera and Gilenya), but it's Gilead's Sovaldi, an $84,000 treatment for hepatitis C that effectively cures more than 90% of patients taking it, that has become the poster child for the next generation of expensive medicine.

G

Source: CVS Caremark

While these therapies are exciting, they are also straining insurers caught between public demands for low monthly insurance premiums and rising expenses tied to prescribing these treatments. As a result, payers are seeking out strategies that lower costs and PBMs are responding with a slate of solutions, including programs designed to improve patient health.

As a result, PBMs like CVS' Caremark business are at the forefront in the battle to deliver patients the medicine they need at a lower price.

Fool-worthy final thoughts
While PBMs like the one run by CVS would seem to be in the sweet spot of rising drug spending, they still face heady challenges.

Lowering costs for payers means that PBM profit margins are thin, particularly given that drugmakers remain eager to earn top dollar for their medicine and insurers are laser focused on improving their own bottom lines.

Having said that, the ability to reduce the cost of drugs is front and center given that 10,000 baby boomers are hitting 65 every day and those over 65 typically fill twice the number of scripts per year compared to those age 45 to 54 years. With soaring healthcare costs likely to continue to pressure payers, PBMs like the one run by CVS may prove to be winners if they can deliver savings that justify clients sticking with them.

Todd Campbell is long Gilead. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends CVS Caremark and recommends and owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers